SLRX
Salarius·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLRX
Salarius Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops cancer therapies
2450 Holcombe Blvd., Suite J-608, Houston, Texas 77021
--
Salarius Pharmaceuticals, Inc., is a biotechnology company incorporated in Delaware on February 26, 2014, and its operations are primarily located in Boston, Massachusetts. The company is developing innovative and proprietary treatments for nighttime leg cramps and spasms associated with severe neuromuscular conditions. The company believes that primary sensory neurons that activate certain receptors reduce repetitive firing, or overexcitement, α-motor neurons, thereby preventing or reducing the frequency and intensity of muscle spasms and twitching. The company also believes that it is the only company to develop a product based on this muscle spasm and spasm inhibition mechanism.
Company Financials
EPS
SLRX has released its 2025 Q2 earnings. EPS was reported at -0.45, versus the expected -1.02, beating expectations. The chart below visualizes how SLRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
